Curcumin changes the polarity of tumor-associated microglia and eliminates glioblastoma

International Journal of Cancer

Volumn 139, Issue 12, 2016, Pages 2838-2849

  Mukherjee, Sumit ^a,b   Baidoo, Juliet ^a,b   Fried, Angela ^b   Atwi, Doaa ^b   Dolai, Sukanta ^a   Boockvar, John ^c,d   Symons, Marc ^c,d   Ruggieri, Rosamaria ^c,d   Raja, Krishnaswami ^b   Banerjee, Probal ^a,b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

brain tumor; cancer; curcumin; microglia; repolarization

Indexed keywords

ARGINASE 1; CD68 ANTIGEN; CURCUMIN; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; STAT1 PROTEIN; AIF1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ARGINASE; BIOLOGICAL MARKER; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; DNA BINDING PROTEIN; LEUKOCYTE ANTIGEN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL DESTRUCTION; CELL POLARITY; CONTROLLED STUDY; EXPLANT; FLOW CYTOMETRY; GL261 CELL LINE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IC50; MALE; MICROGLIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPOLARIZATION; SCAR; TUMOR ASSOCIATED MICROGLIA; TUMOR REGRESSION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; IMMUNOPHENOTYPING; METABOLISM; MORTALITY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; ARGINASE; BIOMARKERS; CELL LINE, TUMOR; CURCUMIN; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GLIOBLASTOMA; HUMANS; IMMUNOPHENOTYPING; INHIBITORY CONCENTRATION 50; MALE; MICE; MICROGLIA; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; STAT1 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988883750     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30398     Document Type: Article

References (48)

1. Purkayastha S, Berliner A, Fernando SS, et al. Curcumin blocks brain tumor formation. Brain Res 2009;1266C:130–8.
2. Kunnumakkara AB, Koca C, Dey S, Gehlot P, Yodkeeree S, Danda D, Sung B, and Aggarwal BB. (2009) Traditional uses of spices: an overview. In: Molecular Targets and Therapeutic Uses of Spices (Aggarwal BB, and Kunnumakkara, A.B., ed). Hackensack, NJ: World Scientific Publishing Co. Pt. Ltd.
3. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008;269:199–225.
4. Langone P, Debata PR, Dolai S, et al. Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin. Int J Cancer 2012;131:E569–E78.
5. Langone P, Debata PR, Inigo JDR, et al. Coupling to a glioblastoma-directed antibody potentiates anti-tumor activity of curcumin. Int J Cancer 2014;135:710–9.
6. Huang W-Y, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer 2010;62:1–20.
7. Hayden EC. Cancer complexity slows quest for cure. Nature 2008;455:148
8. Bhattacharyya S, Mandal D, Saha B, et al. Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 2007;282:15954–64.
9. Shiri S, Alizadeh AM, Baradaran B, et al. Dendrosomal curcumin suppresses metastatic breast cancer in mice by changing M1/M2 macrophage balance in the tumor microenvironment. Asian Pac J Cancer Prev 2015;16:3917–22.
10. Zhang X, Tian W, Cai X, et al. Hydrazinocurcumin encapsuled nanoparticles “Re-Educate” tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression. PLoS One 2013;8:e65896
11. Brantley EC, Guo L, Zhang C, et al. Nitric oxide-mediated tumoricidal activity of murine microglial cells. Transl Oncol 2010;3:380–8.
12. Sarkar S, Döring A, Zemp FJ, et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci 2014;17:46–57.
13. Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro Oncol 2012;14:958–78.
14. Ousman SS, Kubes P. Immune surveillance in the central nervous system. Nat Neurosci 2012;15:1096–101.
15. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264–71.
16. Yang L, Clarke MJ, Carlson BL, et al. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 2008;14:3993–4001.
17. Marczylo TH, Verschoyle RD, Cooke DN, et al. Comparison of systemic availability of curcumin with that of curcumin formulated with phsphatidylcholine. Cancer Chemother Pharmacol 2007;60:171–7.
18. Adayev T, Estephan R, Meserole S, et al. Externalization of phosphatidylserine may not be an early signal of apoptosis in neuronal cells, but only the phosphatidylserine-displaying apoptotic cells are phagocytosed by microglia. J Neurochem 1998;71:1854–64.
19. Fedoroff S, Richardson, A. Generation of mouse astroglia and microglia cultures from mouse neopallium. In: Fedoroff S, Richardson A, eds. Protocols for neural cell culture, 2nd edn. Totowa, New Jersey: Humana Press, 1997. 131–41.
20. Leong C, Zhai D, Kim B, et al. Neural stem cell isolation from the whole mouse brain using the novel FABP7-binding fluorescent dye, CDr3. Stem Cell Res 2013;11:1314–22.
21. Dhuria SV, Hanson LR, Frey WH, II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99:1654–72.
22. Ito D, Imai Y, Ohsawa K, et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Mol Brain Res 1998;57:1–9.
23. Deininger HM, Seid K, Engel S, et al. Allograft inflammatory factor-1 defines a distinct subset of infiltrating macrophages/microglial cells in rat and human gliomas. Acta Neuropathol 2000;100:673–80.
24. Zhou W, Ke SQ, Huang Z, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol 2015;17:170–82.
25. Li Z, Qiu Y, Personett D, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PloS One 2013;8:e71754
26. Ohmori Y, Hamilton TA. Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol 2001;69:598–604.
27. Vakkila J, Demarco RA, Lotze MT. Coordinate NF-kB and STAT1 activation promotes development of myeloid type 1 dendritic cells. Scand J Immunol 2008;67:260–9.
28. Li H-L, Liu C, de Couto G, et al. Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest 2008;118:879–93.
29. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370–7.
30. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid ß oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892–901.
31. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001;21:2895–900.
32. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491–9.
33. Kanai M, Otsuka Y, Otsuka K, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients. Cancer Chemother Pharmacol 2013;71:1521–30.
34. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847–54.
35. Steward WP, Gescher AJ. Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research. Mol Nutr Food Res 2008;52:1005
36. Strimpakos A, Sharma RA. Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials. Antioxid Redox Signal 2008;10:511–45.
37. Debata PR, Curcio GM, Mukherjee S, Banerjee P. Causal factors for brain tumor and targeted strategies. In: Laughoff S, Freund F, eds. Universe of scales: from nanotechnology to cosmology ed, vol. 150. Switzerland: Springer, 2014. 191–204.
38. Ikeda H, Hideshima T, Fulciniti M, et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against cd138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009;15:4028–37.
39. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006;16:92–9.
40. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235–44.
41. Varmus H. The new era in cancer research. Science 2006;312:1162–5.
42. Ifergan I, Kébir H, Bernard M, et al. The blood–brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008;131:785–99.
43. Hagemann T, Biswas S, Lawrence T, et al. Regulation of macrophage function in tumors: the multifaceted role of NF-kB. Blood 2009;113:3139–46.
44. Biswas SK, Lewis CE. NF-kB as a central regulator of macrophage function in tumors. J Leukoc Biol 2010;88:877–84.
45. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 2006;119:1268–75.
46. Marotta LLC, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors. J Clin Invest 2723;121:35.
47. Ito S, Ansari P, Sakatsume M, et al. Interleukin-10 inhibits expression of both interferon a– and interferon gamma–induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999;93:1456–63.
48. Saccani A, Schioppa T, Porta C, et al. p50 nuclear factor-KB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006;66:11432– 40.